TM6SF2 and metabolic dysfunction-associated steatotic liver disease: The TM6SF2 E167K and PNPLA3 I148M polymorphisms may have additive effects on lipid metabolism and the development of NAFLD by upregulating the expression of SREBP-1c and FASN.